Healthcare
SHS exits minority stake Blazejewski Medi-Tech
GP has sold its 24.9% stake in German endoscopy medtech company to peer Erbe two years after investing
Triton’s Pharmanovia tipped as 2023 sale candidate
Exit of specialty pharma group to another PE, minority stake sale with view to IPO on the cards
Nordic exits The Binding Site to trade in 'best ever' deal
GP to reap for 19x money in sale of specialty diagnostics group after 11 years, source says; Five Arrows also exits
Abris Capital ‘confident’ about new fundraise in 2023
Polish GP reinforces its ESG pitch and sees opportunities in rebuilding Ukraine
CVC discards Mehiläinen exit options, focuses on growth
GP bought the Finland-based healthcare service provider in EUR 1.8bn SBO from KKR in 2018
GP Profile: Equistone banks on experience to ride through the next cycle
As the firm contemplates future fundraising, Unquote speaks to partner Tim Swales about the GP’s current outlook
Ardian exits Unither to GIC, IK-led consortium
Existing investors Keensight and Parquest to remain in share capital alongside company's management
Unigestion holds first close for Direct III, eyes EUR 1bn target
GP is continuing concurrent fundraises for vehicles focused on climate impact and emerging managers.
Nordic Capital holds final close for Fund XI on EUR 9bn
Fund is nearly 50% larger than its predecessor and closed after nine months of roadshow
Platform boot camp: Buy-and-build holds fast in healthcare sector
Healthcare M&A has held up well in 2022 versus 2021, offering hope in a challenging market
Houlihan Lokey poaches Hepberger to bolster healthcare team
Rainer Hepberger spent nine years at William Blair and two at Raymond James; brings expertise in medtech
Trilantic-backed Oberberg's auction delayed on market malaise
Factors including valuation discrepancies and debt markets may have slowed the psychiatry clinic's sale
H2 Equity's Optegra sale advances to second round
UK-based ophthalmology business has received NBOs implying an EBITDA multiple of more than 15x
Palatine exits Veincentre in SBO to CBPE
Sale of varicose vein treatment clinic chain is the second exit from 2016-vintage impact fund
The Bolt-Ons Digest – 17 October 2022
Unquote’s selection of the latest add-ons with Equistone's Ligentia, Bridgepoint's Infinigate, Ambienta’s Namirial and more
Qualium bets on high dry powder level to sustain exit valuations
Mid-cap sponsor nears EUR 500m Fund III target with closing expected before year-end, source says
Andera Life Sciences closes sixth fund above target on EUR 456m
Fundraising comes as LPs look for more diversification; VC fund will deploy EUR 5m-15m tickets in therapeutics, medtech
Graphite weighs Compass Fostering exit advised by Harris Williams
Sale unlikely to launch soon given downturn in children fostering services space
Financière Arbevel gears up for new life sciences fund first close
With EUR 100m target second vehicle seeks to attract regional entities of French banks
Agilitas bolsters team with two new hires in London
Philip Krinks, Arnaud Moreels join pan-European sponsor’s ESG and investment teams
Down but not out: UK PE market confident in spite of sterling, macro concerns
Sponsors prepare to weather the storm and seize opportunities emerging from the crisis
Novalpina fund exits Laboratoire XO to Stanley Capital
French drug maker is the first divestment from liquidated fund Novalpina I, now managed by Berkeley Research Group
Blisce eyes USD 250m final close for Fund II by Q1 2023
French VC has received USD 220m in commitments for Europe and US-focused growth vehicle
Apposite closes third healthcare fund on GBP 200m
Specialist GP’s Article 8 vehicle tracks six proprietary health impact objectives for investments